David Sanchez-Infantes1, Ursula A White, Carrie M Elks, Ron F Morrison, Jeffrey M Gimble, Robert V Considine, Anthony W Ferrante, Eric Ravussin, Jacqueline M Stephens. 1. Pennington Biomedical Research Center (D.S.-I., U.A.W., C.M.E., J.M.G., E.R., J.M.S.) and Department of Biological Sciences (J.M.S.), Louisiana State University, Baton Rouge, Louisiana 70808; Department of Nutrition (R.F.M.), UNC-Greensboro, Greensboro, North Carolina 24702; Indiana University School of Medicine (R.V.C.), Indianapolis, Indiana 46202; Department of Medicine (A.W.F.), Columbia University, New York, New York 10032; and Endocrinology Department (D.S.-I.), St Joan de Deu, 08950 Barcelona, Spain.
Abstract
CONTEXT: Adipose tissue is a highly active endocrine organ that secretes many factors that affect other tissues and whole-body metabolism. Adipocytes are responsive to several glycoprotein 130 (gp130) cytokines, some of which have been targeted as potential antiobesity therapeutics. OBJECTIVE: Oncostatin M (OSM) is a gp130 family member known to inhibit adipocyte differentiation in vitro, but its effects on other adipocyte properties are not characterized. The expression of OSM in white adipose tissue (WAT) has not been evaluated in the context of obesity. Thus, our objective was to examine the expression of adipose tissue OSM in obese animals and humans. DESIGN: OSM expression was examined in adipose tissues from mice with diet-induced and genetic obesity and in obese humans as well as in fractionated adipose tissue from mice. Murine adipocytes were used to examine OSM receptor expression and the effects of OSM on adipocytes, including the secretion of factors such as plasminogen activator inhibitor 1 and IL-6, which are implicated in metabolic diseases. RESULTS: OSM expression is increased in rodent and human obesity/type 2 diabetes mellitus. In humans, OSM levels correlate with body weight and insulin and are inversely correlated with glucose disposal rate as measured by hyperinsulinemic-euglycemic clamp. OSM is not produced from the adipocytes in WAT but derives from cells in the stromovascular fraction, including F4/80(+) macrophages. The specific receptor of OSM, OSM receptor-β, is expressed in adipocytes and adipose tissue and increased in both rodent models of obesity examined. OSM acts on adipocytes to induce the expression and secretion of plasminogen activator inhibitor 1 and IL-6. CONCLUSIONS: These data indicate that WAT macrophages are a source of OSM and that OSM levels are significantly induced in murine and human obesity/type 2 diabetes mellitus. These studies suggest that OSM produced from immune cells in WAT acts in a paracrine manner on adipocytes to promote a proinflammatory phenotype in adipose tissue.
CONTEXT: Adipose tissue is a highly active endocrine organ that secretes many factors that affect other tissues and whole-body metabolism. Adipocytes are responsive to several glycoprotein 130 (gp130) cytokines, some of which have been targeted as potential antiobesity therapeutics. OBJECTIVE:Oncostatin M (OSM) is a gp130 family member known to inhibit adipocyte differentiation in vitro, but its effects on other adipocyte properties are not characterized. The expression of OSM in white adipose tissue (WAT) has not been evaluated in the context of obesity. Thus, our objective was to examine the expression of adipose tissue OSM in obese animals and humans. DESIGN: OSM expression was examined in adipose tissues from mice with diet-induced and genetic obesity and in obesehumans as well as in fractionated adipose tissue from mice. Murine adipocytes were used to examine OSM receptor expression and the effects of OSM on adipocytes, including the secretion of factors such as plasminogen activator inhibitor 1 and IL-6, which are implicated in metabolic diseases. RESULTS: OSM expression is increased in rodent and humanobesity/type 2 diabetes mellitus. In humans, OSM levels correlate with body weight and insulin and are inversely correlated with glucose disposal rate as measured by hyperinsulinemic-euglycemic clamp. OSM is not produced from the adipocytes in WAT but derives from cells in the stromovascular fraction, including F4/80(+) macrophages. The specific receptor of OSM, OSM receptor-β, is expressed in adipocytes and adipose tissue and increased in both rodent models of obesity examined. OSM acts on adipocytes to induce the expression and secretion of plasminogen activator inhibitor 1 and IL-6. CONCLUSIONS: These data indicate that WAT macrophages are a source of OSM and that OSM levels are significantly induced in murine and humanobesity/type 2 diabetes mellitus. These studies suggest that OSM produced from immune cells in WAT acts in a paracrine manner on adipocytes to promote a proinflammatory phenotype in adipose tissue.
Authors: Carrie M Elks; Peng Zhao; Ryan W Grant; Hardy Hang; Jennifer L Bailey; David H Burk; Margaret A McNulty; Randall L Mynatt; Jacqueline M Stephens Journal: J Biol Chem Date: 2016-06-20 Impact factor: 5.157
Authors: S Pellitero; I Piquer-Garcia; G Ferrer-Curriu; R Puig; E Martínez; P Moreno; J Tarascó; J Balibrea; C Lerin; M Puig-Domingo; F Villarroya; A Planavila; D Sánchez-Infantes Journal: Int J Obes (Lond) Date: 2017-10-30 Impact factor: 5.095
Authors: Rosalyn D Abbott; Rebecca Y Wang; Michaela R Reagan; Ying Chen; Francis E Borowsky; Adam Zieba; Kacey G Marra; J Peter Rubin; Irene M Ghobrial; David L Kaplan Journal: Adv Healthc Mater Date: 2016-05-19 Impact factor: 9.933
Authors: Paul A Turner; Bhuvaneswari Gurumurthy; Jennifer L Bailey; Carrie M Elks; Amol V Janorkar Journal: Process Biochem Date: 2017-02-06 Impact factor: 3.757